Cost-effectiveness analyses are routinely performed to determine whether the additional cost of a novel therapy is balanced by additional effectiveness. The definitions of costs and effects involve a variety of assumptions, both in general economic terms and with regard to the specific medical setting under consideration. Similarly, differing criteria for acceptability of cost-effectiveness estimates can be used to generate different conclusions regarding cost-effectiveness. The issues and problems inherent in economic evaluation are discussed by an analysis of findings with the platelet glycoprotein IIb/IIIa inhibitor abciximab in the EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) study in high-risk patients undergoing percutaneous transluminal coronary angioplasty.

*Angioplasty, Transluminal, Percutaneous Coronary/economics, 0 (Antibodies, Monoclonal), 0 (Immunoglobulins, Fab), 0 (Platelet Aggregation Inhibitors), 0 (Platelet Glycoprotein GPIIb-IIIa Complex), 143653-53-6 (abciximab), Antibodies, Monoclonal/economics/*therapeutic use, Coronary Disease/drug therapy/economics/*therapy, Cost-Benefit Analysis, Human, Immunoglobulins, Fab/economics/*therapeutic use, Platelet Aggregation Inhibitors/economics/*therapeutic use, Platelet Glycoprotein GPIIb-IIIa Complex/*antagonists & inhibitors, Randomized Controlled Trials, Treatment Outcome, United States
dx.doi.org/10.1016/S0002-8703(98)70302-3, hdl.handle.net/1765/5560
American Heart Journal
Erasmus MC: University Medical Center Rotterdam

van Hout, B.A, Bowman, L, Zelinger, D.J, & Simoons, M.L. (1998). Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. American Heart Journal (Vol. 135). doi:10.1016/S0002-8703(98)70302-3